| Drug General Information |
| Drug ID |
D0PN9R
|
| Former ID |
DNC007402
|
| Drug Name |
R-226161
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C27H32FN3O4
|
| Canonical SMILES |
CC(=CC1=CC=C(C=C1)F)CN2CCN(CC2)CC3C4COC5=CC(=C(C=C5C4=N<br />O3)OC)OC
|
| InChI |
1S/C27H32FN3O4/c1-18(12-19-4-6-20(28)7-5-19)15-30-8-10-31(11-9-30)16-26-22-17-34-23-14-25(33-3)24(32-2)13-21(23)27(22)29-35-26/h4-7,12-14,22,26H,8-11,15-17H2,1-3H3/b18-12+/t22-,26-/m0/s1
|
| InChIKey |
UCNOTTVNPRSTFW-XSFNXXSESA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Alpha-2C adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| Sodium-dependent serotonin transporter |
Target Info |
Inhibitor |
[1]
|
| Alpha-1A adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
| Alpha-2B adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
| D(3) dopamine receptor |
Target Info |
Inhibitor |
[1]
|
| Sodium-dependent dopamine transporter |
Target Info |
Inhibitor |
[1]
|
| Substance-P receptor |
Target Info |
Inhibitor |
[1]
|
| Alpha-2A adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
| Histamine H1 receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04726:Serotonergic synapsehsa04020:Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
AMPK signaling pathway
|
|
Adrenergic signaling in cardiomyocytes
|
|
Vascular smooth muscle contraction
|
|
Salivary secretionhsa04022:cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction
|
|
Dopaminergic synapsehsa04728:Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Alcoholismhsa04020:Calcium signaling pathway
|
|
Measleshsa04022:cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway
|
|
Inflammatory mediator regulation of TRP channels
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP04373:5HT1 type receptor mediated signaling pathway
|
|
5HT2 type receptor mediated signaling pathway
|
|
5HT3 type receptor mediated signaling pathway
|
|
5HT4 type receptor mediated signaling pathwayP00002:Alpha adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00001:Adrenaline and noradrenaline biosynthesis
|
|
Parkinson disease
|
|
Dopamine receptor mediated signaling pathwayP06959:CCKR signaling map STP00002:Alpha adrenergic receptor signaling pathwayP04385:Histamine H1 receptor mediated signaling pathway
|
|
Pathway Interaction Database
|
Alpha-synuclein signaling
|
|
Reactome
|
Adrenoceptors
|
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
G alpha (i) signalling events
|
|
G alpha (z) signalling events
|
|
Surfactant metabolismR-HSA-390696:Adrenoceptors
|
|
G alpha (q) signalling events
|
|
G alpha (12/13) signalling eventsR-HSA-390696:Adrenoceptors
|
|
G alpha (z) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling eventsR-HSA-442660:Na+/Cl- dependent neurotransmitter transportersR-HSA-416476:G alpha (q) signalling eventsR-HSA-390696:Adrenoceptors
|
|
Surfactant metabolismR-HSA-390650:Histamine receptors
|
|
WikiPathways
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Platelet Aggregation (Plug Formation)
|
|
Integration of energy metabolism
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP727:Monoamine Transport
|
|
SIDS Susceptibility Pathways
|
|
NRF2 pathway
|
|
Synaptic Vesicle Pathway
|
|
Serotonin Transporter ActivityWP58:Monoamine GPCRs
|
|
Calcium Regulation in the Cardiac Cell
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
Endothelin Pathways
|
|
GPCR downstream signaling
|
|
AMPK SignalingWP58:Monoamine GPCRs
|
|
GPCR downstream signalingWP58:Monoamine GPCRs
|
|
Nicotine Activity on Dopaminergic Neurons
|
|
GPCRs, OtherWP727:Monoamine Transport
|
|
Dopaminergic Neurogenesis
|
|
Parkinsons Disease Pathway
|
|
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
|
|
Neurotransmitter Clearance In The Synaptic CleftWP706:SIDS Susceptibility Pathways
|
|
Spinal Cord Injury
|
|
Peptide GPCRs
|
|
IL-4 Signaling Pathway
|
| References |
| REF 1 | Bioorg Med Chem. 2007 Jun 1;15(11):3649-60. Epub 2007 Mar 21.Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-adrenoceptor antagonism. |
|---|
